| Developers: | Ibex Medical Analytics |
| Date of the premiere of the system: | April, 2018 |
2018: Implementation of the first-ever digital AI-diagnostic system of cancer
On April 16, 2018 the developer of the IBEX Medical Analytics technologies using the artificial intelligence (AI) for the first time in the world used in clinical practice a digital system on the basis of AI for diagnosis of oncological diseases.
The Israeli company IBEX developed the software which identifies different types of samples of a biopsy of a prostate, including a prostate cancer of different stages and other clinically significant statuses. The algorithm IBEX uses modern methods of artificial intelligence and machine learning and was trained on several thousand images received from hundreds of laboratories.
A system under the name Second Read which the IBEX unrolled at institute of pathological anatomy Maccabi Healthcare Services — one of the largest health facilities in Israel and the strategic partner of the IBEX. 160,000 histologic samples a year from which about 700 are received at a tonkoigolny biopsy of a prostate are estimated at laboratories of institute. The system of repeated testing the IBEX probation experimental period during which it should check prostate biopsy samples after laboratory doctors undergoes and reveal false-negative results of inspections on a zlokchestvuyenny tumor.
Soon after implementation a system identified the suspicious sample of a biopsy of a prostate browsed by the pathologist only a few hours ago. At a repeated research the prostate cancer (adenocarcinoma) of the first stage was confirmed. Bug fix caused change of strategy of treatment.
 | We are glad to become the first company which implemented a diagnostic system based on AI in work of pathoanatomical laboratory. Huge potential of artificial intelligence should be used for rescue of human lives, and it is very pleasant to us that a system already helped one of patients. Now we are ready to throw all forces on making our system commercially available — the CEO and the cofounder of IBEX Medical Analytics Joseph Mossel said.[1] |  |
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |